

	Incubation Time:	20 minutes
	Result:	Completely inhibited Phosphorylation of SMAD2.
In Vivo	AZ12601011 (50mg/kg; oral gavage; twice daily; for 25 days) inhibits tumour growth and metastasis in vivo ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Female BALB/c mice at greater than 18g with tumour ^[1]
	Dosage:	50mg/kg
	Administration:	Oral gavage; twice daily; for 25 days
	Result:	Inhibited tumour growth and metastasis in vivo.

CUSTOMER VALIDATION

- Rheumatology. 2021 Sep 24;keab725.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Spender LC, et al. Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors. Mol Pharmacol. 2019 Feb;95(2):222-234.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA